HANGZHOU, China, July 27 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. , one of mainland China’s leading pharmaceutical companies, today announced that the Company has successfully concluded the Phase I trials for gene-therapy anti-tumor drug Rh-Apo2L.
Rh-Apo2L was approved for clinical trials in May 2005 by China’s State Food and Drug Administration (SFDA). The trials were conducted from September 2005 through May 2006 at the Chinese Academy of Medical Sciences Oncology Hospital in Beijing, China.
The Phase I clinical trials included 20 patients with advanced-stage malignant tumors. The researched cancer types included non-Hodgkin lymphoma, sarcoma, adrenal gland cortical tumors, non-small cell lung cancer, colorectal cancer, and parotid gland capsule adenocarcinoma. Researchers found that clinical trials support the belief that Rh-Apo2L reduces the tumor size of non-Hodgkin lymphoma, sarcoma and adrenal gland cortical tumors. Additionally, researchers found that Rh-Apo2L also affects the tumor size of non-small cell lung cancer, colorectal cancer and parotid gland capsule adenocarcinoma. Specific curative results of Rh-Apo2L will be confirmed in Phase II and III clinical trials.
Jin Biao, Aida Pharmaceuticals’ Chairman, stated, “The preliminary results of the Phase I trials indicate that Rh-Apo2L is effective in reducing the size of tumors through a genetic process to the benefit of patients. Not only is tumor size reduced, but patients only experienced the nominal side-effects which are common in similar cancer fighting treatments. However, more severe side effects such as blood cell toxicity were not apparent. To date, our studies on Rh-Apo2L indicate that it may be one of the safest drugs for tumor therapy available. This is a great success for China’s biotechnology industry and an encouraging event for us at Aida.”
Aida Pharmaceuticals is scheduling a press conference next month to discuss the conclusion and positive results of Rh-Apo2L Phase I trials. The Company plans to imminently apply for Phase II and Phase III clinical trials with the SFDA. The Company also reiterates its previous statement that it anticipates the completion of all clinical trials by the end of 2007 and that Rh-Apo2L will receive all regulatory approval needed for commercialization in 2008.
About Rh-Apo2L:
Rh-Apo2L is an anti-tumor biological agent researched and developed by Shanghai Qiaer Biotechnology Co., Ltd., a newly acquired subsidiary of Aida Pharmaceuticals. Rh-Apo2L is a broad spectrum genetic cell apoptosis (cell- killing) agent, which can be used for the treatment of a variety of tumors. Research and Development of Rh-Apo2L is sponsored and supported by several national and municipal funds. One patent of Rh-Apo2L has been granted by Chinese Patent Bureau, two additional patents are currently in process.
About Aida Pharmaceuticals:
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company’s mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category “A” drug by the State Food and Drug Administration of China.
Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Gary Geraci (617) 723-2373 gary@equityperfgp.comhttp://www.equityperformancegroup.com Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management’s current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.
Aida Pharmaceuticals, Inc.
CONTACT: Investor Relations: Gary Geraci of Equity Performance Group,+1-617-723-2373, gary@equityperfgp.com
Web site: http://www.equityperformancegroup.com/
